In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Evotec issues stock valued at $161mm to buy Renovis

Executive Summary

German biotech Evotec AG has agreed to acquire publicly traded Renovis (mostly neurology and inflammation drug candidates) in a transaction valued at $161mm in stock.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Full Acquisition
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register